OKYO PHARMA LTD (OKYO) Stock Price, Forecast & Analysis
NASDAQ:OKYO • GG00BMFG5F62
OKYO Key Statistics, Chart & Performance
The current stock price of OKYO is 1.72 USD. In the past month the price decreased by -21.46%. In the past year, price increased by 36.52%.
OKYO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OKYO. When comparing the yearly performance of all stocks, OKYO turns out to be only a medium performer in the overall market: it outperformed 67.68% of all stocks.
OKYO Financial Highlights
Over the last trailing twelve months OKYO reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 69.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OKYO Forecast & Estimates
9 analysts have analysed OKYO and the average price target is 8.5 USD. This implies a price increase of 394.18% is expected in the next year compared to the current price of 1.72.
OKYO Ownership
OKYO Latest News, Press Relases and Analysis
OKYO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.47 | 397.113B | ||
| AMGN | AMGEN INC | 16.83 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.12 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.55 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.45 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.36 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.09 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OKYO
Company Profile
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
Company Info
OKYO PHARMA LTD
Floor 4, 14/15 Conduit St
London GB
Employees: 4
Phone: 442074952379
OKYO PHARMA LTD / OKYO FAQ
What does OKYO PHARMA LTD do?
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
What is the current price of OKYO stock?
The current stock price of OKYO is 1.72 USD. The price increased by 1.18% in the last trading session.
What is the dividend status of OKYO PHARMA LTD?
OKYO does not pay a dividend.
What is the ChartMill rating of OKYO PHARMA LTD stock?
OKYO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for OKYO stock?
OKYO PHARMA LTD (OKYO) currently has 4 employees.
What is the market capitalization of OKYO stock?
OKYO PHARMA LTD (OKYO) has a market capitalization of 37.44M USD. This makes OKYO a Nano Cap stock.
What is the outstanding short interest for OKYO PHARMA LTD?
The outstanding short interest for OKYO PHARMA LTD (OKYO) is 2.19% of its float.